PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging and associated solutions, today announced a reinforced management team with the appointment of Jamie Milas to the position of Vice President, Global Marketing. Additional alterations to the management team include Hervé Legrand’s transition to Director of Business Development and Bernard Ismael’s, who joins EOS as Director of Quality & Regulatory.
Ms. Milas joins EOS imaging after seven years as the Global Marketing Manager for Biomedical Engineering at Materialise, a leader in additive manufacturing (also known as 3D printing). In her role at EOS, Ms. Milas will pursue the current company strategy for turning the EOS equipment into a standard of care. She will also leverage her years of orthopedic experience to develop the Company’s software, services and consumable offerings being developed with the EOS platform.
Mr. Legrand has been with EOS imaging since 2009 and has held Marketing and Sales positions and most recently that of VP of Global Marketing. In his new role, Mr. Legrand will advance EOS’ global business development initiatives and partnerships.
Mr. Ismael joined EOS imaging after holding several leading quality and regulatory positions at Boston Scientific, Sebia, Medtronic and Porgès/Coloplast.
Marie Meynadier, CEO of EOS imaging, said, “I am very excited to welcome Jamie and Bernard to the team. Their contribution will be key to the Company’s growth and progress in turning EOS a standard of care, and Jamie’s experience will be a strong asset as we are growing our service and consumable offerings. This reinforced and remodeled management team puts us in good standing as EOS continues to grow as the pioneer in orthopedic medical imaging.”
The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans, as well as related software solutions. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.
For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 3rd quarter of 2015, on October 19, 2015 (after market).
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled Georges Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and Singapore.